Antibiotic Dosing for Children by Weight: Quick Reference Guide
TL;DR
- Antibiotic dosing in children is weight-based (mg/kg/day), not age-based — accurate weight in kilograms is essential before every prescription.
- High-dose amoxicillin (80–90 mg/kg/day) is first-line for acute otitis media and suspected resistant pneumococcal infections per AAP guidelines.
- Never exceed listed maximum adult doses, even if the weight-based calculation suggests a higher number.
- Duration matters: shorter courses (5–7 days) are appropriate for many infections in children ≥2 years, but younger children often require 10 days.
- Always recheck weight, allergy history, and renal function before dispensing — dosing errors are the leading cause of preventable adverse drug events in pediatrics.
Antibiotic dosing for children by weight remains one of the most frequent — and most error-prone — calculations in pediatric practice. Unlike adults, who receive relatively standardized doses, children require individualized milligram-per-kilogram calculations that change as they grow. A dose appropriate for a 10 kg toddler may be dangerously inadequate for a 30 kg school-age child, or dangerously excessive if the decimal point shifts. The AAP, IDSA, and NICE all emphasize weight-based prescribing as the standard of care for pediatric anti-infective therapy.
This guide consolidates dosing for six of the most commonly prescribed oral pediatric antibiotics — amoxicillin, amoxicillin–clavulanate, azithromycin, cephalexin, cefdinir, and trimethoprim–sulfamethoxazole (TMP–SMX) — into a practical reference with per-kilogram ranges, maximum doses, and duration guidance drawn from current guidelines.
Why Weight-Based Dosing Is Non-Negotiable in Pediatrics
Children are not small adults. Body composition, organ maturation, drug metabolism, and volume of distribution all change dramatically from infancy through adolescence. A neonate's renal clearance may be one-third that of a 6-year-old; a toddler's hepatic metabolism may proportionally exceed an adult's. These pharmacokinetic differences mean that flat dosing by age bracket produces unpredictable serum levels, risking both treatment failure and toxicity.
The AAP's policy statement on prevention of medication errors in pediatrics specifically identifies incorrect dosing as the most common prescribing error in children, with weight-based miscalculation as the primary driver. NICE similarly mandates per-kilogram dosing for all pediatric antimicrobials in its guidelines.
Key practical points:
- Always weigh the child in kilograms at the visit — do not rely on parental estimates or historical weights. A child can gain 2–3 kg between sick visits.
- Use actual body weight, not ideal body weight, for most antibiotics (exceptions exist for significantly obese children, where clinical judgment applies).
- Calculate the dose, then cross-check against the maximum adult dose — the weight-based calculation is a ceiling, not a floor.
- Confirm the concentration of the liquid formulation — amoxicillin comes in 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, and 400 mg/5 mL suspensions. Dispensing the wrong concentration without adjusting volume is a common source of error.
High-Dose vs. Standard-Dose Amoxicillin: When and Why
Amoxicillin is the most prescribed pediatric antibiotic worldwide. The distinction between standard-dose (40–45 mg/kg/day) and high-dose (80–90 mg/kg/day) prescribing is clinically important and frequently tested.
Standard dose (40–45 mg/kg/day) is appropriate for:
- Uncomplicated streptococcal pharyngitis (Group A Streptococcus)
- Mild urinary tract infections (where susceptibility is confirmed)
- Step-down from parenteral therapy for susceptible organisms
High dose (80–90 mg/kg/day) is recommended by the AAP and IDSA for:
- Acute otitis media (AOM) — first-line therapy per the 2013 AAP Clinical Practice Guideline, targeting penicillin-intermediate Streptococcus pneumoniae (MIC 2–4 µg/mL), which requires higher middle-ear fluid concentrations
- Community-acquired pneumonia when pneumococcal resistance is a concern
- Acute bacterial sinusitis per IDSA 2012 guidelines
- Regions or populations with >10% prevalence of penicillin-nonsusceptible pneumococci (which now includes most of the United States and much of Europe)
The pharmacological rationale is straightforward: amoxicillin's bactericidal activity is time-dependent, and higher dosing extends the duration that free drug concentration exceeds the MIC of intermediately resistant pneumococci. The 80–90 mg/kg/day regimen achieves middle-ear fluid concentrations above the 2 µg/mL breakpoint for approximately 50–60% of the dosing interval — sufficient for clinical cure in most cases.
Comprehensive Dosing Table: Six Core Pediatric Antibiotics
The following table summarizes weight-based dosing for the most commonly prescribed oral pediatric antibiotics. All doses reflect current AAP, IDSA, and NICE recommendations.
| Antibiotic | Indication | Dose (mg/kg/day) | Frequency | Max Daily Dose | Typical Duration | Notes |
|---|---|---|---|---|---|---|
| Amoxicillin (standard) | GAS pharyngitis, mild UTI | 40–50 | q12h or q8h | 1500 mg/day | 10 days (pharyngitis) | Oral suspension: 200 or 400 mg/5 mL preferred for BID dosing |
| Amoxicillin (high-dose) | AOM, sinusitis, CAP | 80–90 | q12h | 3000 mg/day | 10 days (<2 yr); 5–7 days (≥2 yr, mild AOM) | First-line AOM per AAP 2013 |
| Amoxicillin–clavulanate (standard) | UTI, skin/soft tissue | 25–45 (amoxicillin component) | q12h | 1750 mg amox/day | 7–10 days | Use 7:1 formulation for standard dosing |
| Amoxicillin–clavulanate (high-dose) | Resistant AOM, sinusitis | 90 (amoxicillin component) | q12h | 3000 mg amox/day | 10 days | Use 14:1 formulation (600 mg/5 mL) to limit clavulanate to ≤6.4 mg/kg/day |
| Azithromycin | AOM (second-line), CAP (Mycoplasma), pharyngitis (pen-allergic) | 10 mg/kg day 1, then 5 mg/kg days 2–5 | q24h | 500 mg day 1, 250 mg days 2–5 | 5 days | Alternative: 10 mg/kg/day × 3 days for AOM |
| Cephalexin | Skin/soft tissue (MSSA), UTI, bone/joint step-down | 25–50 (up to 75–100 for osteoarticular) | q6h or q8h | 4000 mg/day | 7–10 days (skin); varies (osteoarticular) | First-generation cephalosporin; poor CNS penetration |
| Cefdinir | AOM, sinusitis, pharyngitis (second-line) | 14 | q12h or q24h | 600 mg/day | 5–10 days | Turns stool red with iron-containing products (harmless) |
| TMP–SMX | UTI, AOM (resistant), skin/soft tissue (CA-MRSA) | 8–12 (TMP component) | q12h | 320 mg TMP/day | 7–10 days (UTI); 5–7 days (AOM) | Contraindicated <2 months; avoid in G6PD deficiency |
How to use this table: Multiply the child's weight in kilograms by the mg/kg/day dose, then divide by the number of daily doses to determine each individual dose. For example, a 15 kg child with AOM receiving high-dose amoxicillin: 15 × 90 = 1350 mg/day ÷ 2 doses = 675 mg per dose.
Practical Dosing Calculations: Worked Examples
To illustrate the pediatric antibiotic dose calculator approach in practice, consider the following scenarios.
Example 1 — Amoxicillin for AOM in a 12 kg toddler (18 months):
- Target dose: 90 mg/kg/day = 1080 mg/day
- Frequency: q12h → 540 mg per dose
- Using 400 mg/5 mL suspension: 540 ÷ 80 (mg/mL) = 6.75 mL per dose
- Max dose check: 1080 mg/day < 3000 mg/day ✓
- Duration: 10 days (child <2 years per AAP)
Example 2 — Azithromycin pediatric dosing for a 25 kg child with atypical pneumonia:
- Day 1: 10 mg/kg = 250 mg (one dose)
- Days 2–5: 5 mg/kg = 125 mg daily
- Max dose check: 250 mg < 500 mg ✓
- Using 200 mg/5 mL suspension: Day 1 = 6.25 mL; Days 2–5 = 3.125 mL (round to 3 mL)
Example 3 — Cephalexin dose for a 32 kg child with cellulitis:
- Target dose: 50 mg/kg/day = 1600 mg/day
- Frequency: q8h → ~533 mg per dose → use 500 mg capsules q8h
- Max dose check: 1600 mg/day < 4000 mg/day ✓
- Duration: 7 days, with reassessment at 48–72 hours
Side Effects, Tolerability, and Monitoring
All antibiotics carry risk. In children, gastrointestinal effects predominate, but allergic reactions, dysbiosis, and organ-specific toxicity must be monitored.
| Antibiotic | Common Side Effects | Serious/Rare Adverse Effects | Monitoring Considerations |
|---|---|---|---|
| Amoxicillin | Diarrhea (5–10%), rash (3–5%), nausea | Anaphylaxis (<0.05%), C. difficile colitis, maculopapular rash with EBV | Differentiate amoxicillin rash from true allergy — non-urticarial maculopapular rash in setting of viral illness is usually non-allergic |
| Amoxicillin–clavulanate | Diarrhea (9–20%), diaper dermatitis | Hepatotoxicity (rare, primarily with prolonged courses), C. difficile | Higher GI side effects than amoxicillin alone due to clavulanate; use highest ratio formulation to minimize |
| Azithromycin | Abdominal pain, diarrhea, nausea (5–8%) | QT prolongation (rare), IHPS in neonates <6 weeks, hepatotoxicity | Avoid with other QT-prolonging agents; FDA boxed warning regarding cardiac risk in at-risk populations |
| Cephalexin | Diarrhea, nausea, abdominal discomfort | Anaphylaxis (cross-reactivity with penicillin ~1–2%), C. difficile | Safe in most penicillin-allergic patients unless history of anaphylaxis to penicillin |
| Cefdinir | Diarrhea, reddish stool (with iron) | Rare hypersensitivity | Red stool from iron chelation is benign — counsel families to avoid unnecessary ED visits |
| TMP–SMX | Nausea, vomiting, rash | Stevens-Johnson syndrome, agranulocytosis, hyperkalemia, hemolytic anemia in G6PD deficiency | Monitor CBC if prolonged use; avoid in infants <2 months (kernicterus risk) |
Key tolerability strategies:
- Administer amoxicillin and amoxicillin–clavulanate with food to reduce GI upset.
- Probiotics (Lactobacillus spp. or Saccharomyces boulardii) may reduce antibiotic-associated diarrhea — some evidence supports concurrent use, though AAP stops short of a universal recommendation.
- Complete the full prescribed course — counsel parents that stopping early when the child "feels better" promotes resistance and risks relapse.
Contraindications, Drug Interactions, and Allergy Cross-Reactivity
Absolute contraindications:
- Amoxicillin / amoxicillin–clavulanate: documented IgE-mediated (type I) hypersensitivity to any penicillin. Prior cholestatic jaundice with amoxicillin–clavulanate.
- Azithromycin: known hypersensitivity to macrolides; history of cholestatic jaundice/hepatic dysfunction with prior azithromycin use.
- Cephalexin / cefdinir: anaphylaxis to any cephalosporin. Use with caution in penicillin anaphylaxis — cross-reactivity between penicillins and first-generation cephalosporins is approximately 1–2%, considerably lower than the historically cited 10%.
- TMP–SMX: infants <2 months (bilirubin displacement → kernicterus risk), megaloblastic anemia due to folate deficiency, severe hepatic or renal impairment, documented G6PD deficiency (risk of hemolytic anemia).
Clinically significant drug interactions:
- Amoxicillin–clavulanate + methotrexate: reduced methotrexate clearance → toxicity risk.
- Azithromycin + antacids (Al/Mg-containing): reduced absorption — separate by ≥2 hours.
- Azithromycin + QT-prolonging drugs (ondansetron, fluconazole): additive QT prolongation.
- TMP–SMX + warfarin: enhanced anticoagulant effect via CYP2C9 inhibition.
- TMP–SMX + ACE inhibitors/ARBs/potassium-sparing diuretics: risk of severe hyperkalemia — uncommon in children but relevant in adolescents on these medications.
- Cefdinir + iron supplements or iron-fortified formula: chelation produces red stools (benign) and may reduce cefdinir absorption — separate by ≥2 hours.
Special Populations
Neonates (0–28 days)
Oral antibiotics have a limited role in neonates. Most neonatal infections require parenteral therapy. None of the six antibiotics covered here are routinely used as monotherapy in neonates for serious infections. TMP–SMX is contraindicated under 2 months. Azithromycin has been associated with infantile hypertrophic pyloric stenosis (IHPS) in infants under 6 weeks — the FDA notes this risk in labeling, and alternatives should be preferred when possible.
Obese children
Weight-based dosing using actual body weight is generally recommended for obese children for the antibiotics covered here, as most have a wide therapeutic index. However, when calculated doses significantly exceed the maximum adult dose, cap at the adult maximum. Limited pharmacokinetic data exist for obese pediatric patients; clinical judgment and infectious disease consultation are appropriate for complex cases.
Renal impairment
Amoxicillin, cephalexin, cefdinir, and TMP–SMX are renally cleared and require dose adjustment when GFR is significantly reduced. Azithromycin does not require renal dose adjustment. Specific dose reductions should follow current drug labeling or institutional protocols — this is uncommon in otherwise healthy children but relevant in those with known renal disease.
Penicillin allergy
True penicillin allergy is overdiagnosed in children. Studies consistently show that >90% of children labeled "penicillin-allergic" tolerate penicillins on formal challenge. The AAP encourages penicillin allergy delabeling where safe to do so.
For children with confirmed IgE-mediated penicillin allergy:
- Cephalexin and cefdinir may be used with caution — cross-reactivity risk is low (~1–2%) with modern cephalosporins.
- Azithromycin is a safe alternative for respiratory infections.
- TMP–SMX is an option for UTI and CA-MRSA skin infections.
Red Flags — When to Seek Immediate Medical Attention
Parents and caregivers should be counseled to seek urgent medical evaluation if a child on antibiotics develops any of the following:
- Signs of anaphylaxis: hives, facial/lip/tongue swelling, wheezing, difficulty breathing, or cardiovascular collapse — call emergency services immediately
- No improvement within 48–72 hours of starting antibiotics — may indicate resistant organism, wrong diagnosis, or complications (abscess, empyema)
- High fever (>40°C / 104°F) persisting beyond 48 hours of therapy
- Severe or bloody diarrhea — raises concern for Clostridioides difficile infection
- Rash with mucosal involvement (mouth sores, eye redness, blistering) — concern for Stevens-Johnson syndrome, particularly with TMP–SMX
- Jaundice or dark urine — hepatotoxicity, particularly with amoxicillin–clavulanate or azithromycin
- Lethargy, poor feeding, or toxic appearance in any child — these warrant emergency evaluation regardless of antibiotic therapy
- Recurrent infections within weeks of completing therapy — may indicate underlying immunodeficiency, anatomic abnormality, or resistant pathogen
Frequently Asked Questions
Q: Can I use a pediatric antibiotic dose calculator app instead of manual calculation? A: Dose calculator tools can be useful as a cross-check, but they should never replace clinical judgment. Verify the app uses current guidelines (AAP, IDSA, or NICE), confirm the suspension concentration in the app matches what was dispensed, and always double-check the output against published mg/kg ranges. The calculation itself is simple — it is the clinical decision (which antibiotic, which dose tier, which duration) that requires professional expertise.
Q: My child weighs 40 kg — should they get adult doses? A: Not automatically. A child who weighs 40 kg may be 8 or 14 years old, and there is more to dosing than weight alone. Calculate the weight-based dose and use the adult maximum dose as a ceiling. For example, amoxicillin at 90 mg/kg/day for a 40 kg child is 3600 mg/day — but the usual adult maximum is 3000 mg/day, so you would cap at 3000 mg/day. Some guidelines transition to adult dosing at 40 kg for certain antibiotics; follow your local institutional protocol.
Q: Is high-dose amoxicillin safe? I am worried about giving so much antibiotic. A: High-dose amoxicillin (80–90 mg/kg/day) has been extensively studied in children and has an excellent safety profile. The main increase in side effects compared to standard dosing is slightly more diarrhea. The AAP has recommended high-dose amoxicillin as first-line for AOM since 2004 (reaffirmed 2013), and decades of clinical use support its safety. The risk of undertreating a resistant infection outweighs the marginal increase in GI side effects.
Q: Can amoxicillin be given twice daily instead of three times daily? A: Yes. Current AAP guidelines for AOM specifically recommend twice-daily (q12h) dosing for high-dose amoxicillin, which improves adherence without compromising efficacy. For standard-dose amoxicillin in pharyngitis, twice-daily dosing with 50 mg/kg/day (using 200 or 400 mg/5 mL suspensions) is also well-supported. Three-times-daily dosing is an older convention and is generally no longer preferred for most indications.
Q: What if my child vomits within 30 minutes of taking the antibiotic? A: If the child vomits within 15–20 minutes of a dose, it is generally reasonable to repeat the full dose. If vomiting occurs 30–60 minutes after dosing, most of the drug has likely been absorbed, and repeating the dose is not recommended. Persistent vomiting may necessitate a change to an antibiotic with once-daily dosing (azithromycin, cefdinir) or, in severe cases, parenteral therapy.
Q: How do I measure liquid antibiotic doses accurately? A: Always use the oral syringe provided with the prescription — never a household teaspoon, which can vary by up to 50% in volume. For doses less than 5 mL, an oral syringe is significantly more accurate than a dosing cup. Draw up the exact volume, administer directly into the cheek (not the back of the throat), and rinse the syringe after each use.
Q: Why does my child's stool turn red on cefdinir? A: This is a benign chemical reaction between cefdinir and iron (from iron-fortified formula, supplements, or diet). The reddish discoloration of stool is not blood and does not indicate any harm. It resolves within days of stopping cefdinir or separating cefdinir and iron intake by at least 2 hours. Despite being harmless, this phenomenon generates significant parental anxiety and ED visits — advance counseling prevents unnecessary evaluations.
Q: Should I give my child probiotics with antibiotics? A: Evidence from multiple meta-analyses suggests that Lactobacillus rhamnosus GG and Saccharomyces boulardii may reduce the incidence and duration of antibiotic-associated diarrhea in children. While the AAP has not issued a blanket recommendation, many pediatric infectious disease specialists support concurrent probiotic use for children on antibiotics expected to cause significant GI disruption (particularly amoxicillin–clavulanate). Administer probiotics at least 2 hours apart from the antibiotic dose.
References
-
Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964–e999. PMID: 23439909
-
Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25–e76. PMID: 21880587
-
Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72–e112. PMID: 22438350
-
NICE. Otitis media (acute): antimicrobial prescribing. NICE guideline NG91. 2018. nice.org.uk/guidance/ng91
-
NICE. Sinusitis (acute): antimicrobial prescribing. NICE guideline NG79. 2017. nice.org.uk/guidance/ng79
-
Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86–e102. PMID: 22965026
-
FDA. Label: Amoxicillin capsules, tablets, and powder for oral suspension. DailyMed
-
Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology — drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167. PMID: 13679531
-
Guo Q, Goldenberg JZ, Humphrey C, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;(4):CD004827. PMID: 31039287
-
Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: a cohort study. J Allergy Clin Immunol. 2014;133(3):790–796. PMID: 24188976
-
AAP Committee on Drugs. Prevention of medication errors in the pediatric inpatient setting. Pediatrics. 2003;112(2):431–436. PMID: 12897304
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in hospital and community pharmacy practice, with particular expertise in pediatric therapeutics, antimicrobial stewardship, and medication safety. He holds a Doctor of Pharmacy degree and has contributed to institutional formulary management and clinical protocol development across multiple healthcare settings. Dr. Ozarchuk writes for PillsCard.com to bridge the gap between clinical pharmacy evidence and practical patient education, ensuring that complex pharmacological information is accessible without sacrificing accuracy.
Medical Disclaimer
This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The dosing information provided reflects published guidelines current at the time of writing but may not account for individual patient factors, institutional protocols, or emerging evidence. Always consult a qualified healthcare professional — physician, pharmacist, or nurse practitioner — before administering any antibiotic to a child. Dosing decisions must incorporate the child's weight, age, renal function, allergy history, local resistance patterns, and clinical presentation. Do not adjust, start, or stop antibiotic therapy based solely on the information in this article. In case of a medical emergency, contact your local emergency services immediately. PillsCard.com and its contributors assume no liability for clinical decisions made based on this content.